Coadministration has not been studied. Mefenamic acid is metabolised by CYP2C9 and additionally glucuronidated by UGT2B7 and UGT1A9. Doravirine is metabolized by CYP3A4 and does not inhibit or induce CYP or UGT enzymes. Lamivudine and tenofovir are eliminated renally. No pharmacokinetic interaction is expected with doravirine and lamivudine. However, mefenamic acid could potentially decrease the renal elimination of tenofovir as in vitro data suggest that mefenamic acid inhibits the renal transporter OAT1. Coadministration could potentially result in increased risk of nephrotoxicity with tenofovir-DF. The risk is increased if an NSAID is used for a long duration, if the patient has a pre-existing renal dysfunction, has a low body weight, or receives other drugs that may increase tenofovir exposure. Cases of acute renal failure after initiation of high dose or multiple NSAIDs have been reported in patients treated with tenofovir-DF and with risk factors for renal dysfunction. Alternatives to NSAIDs should be considered in patients at risk for renal dysfunction. If tenofovir-DF is co-administered with an NSAID, renal function should be monitored adequately.